Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma

This study has been completed.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00631579
First received: February 26, 2008
Last updated: October 1, 2009
Last verified: October 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2004
  Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
No publications provided by Sanofi

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):